Malignancy and the Risks of Biologic Therapies: Current Status.
Identifieur interne : 001754 ( Main/Exploration ); précédent : 001753; suivant : 001755Malignancy and the Risks of Biologic Therapies: Current Status.
Auteurs : Raphaèle Seror [France] ; Xavier Mariette [France]Source :
- Rheumatic diseases clinics of North America [ 1558-3163 ] ; 2017.
Descripteurs français
- KwdFr :
- MESH :
- effets indésirables : Antirhumatismaux, Produits biologiques.
- immunologie : Rhumatismes, Tumeurs.
- traitement médicamenteux : Rhumatismes.
- Humains, Tumeurs.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antirheumatic Agents, Biological Products.
- chemically induced : Neoplasms.
- drug therapy : Rheumatic Diseases.
- immunology : Neoplasms, Rheumatic Diseases.
- Humans.
Abstract
Cancer is a common event in patients with rheumatic diseases. In some cases, the disease, its risk factors, or its treatment could play a role in favoring cancer. This article analyzes the current knowledge on the risk of malignancy associated with biologics in rheumatic diseases and discusses some methodological issues to be considered when evaluating the association between disease, treatments, and the risk of cancer. This article focuses on the risk of overall malignancy but also of skin cancer, lymphoma, and recurrent cancer associated with all biologics marketed for the treatment of rheumatic diseases.
DOI: 10.1016/j.rdc.2016.09.006
PubMed: 27890173
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000C91
- to stream PubMed, to step Curation: 000C91
- to stream PubMed, to step Checkpoint: 000B14
- to stream Ncbi, to step Merge: 001400
- to stream Ncbi, to step Curation: 001400
- to stream Ncbi, to step Checkpoint: 001400
- to stream Main, to step Merge: 001753
- to stream Main, to step Curation: 001754
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Malignancy and the Risks of Biologic Therapies: Current Status.</title><author><name sortKey="Seror, Raphaele" sort="Seror, Raphaele" uniqKey="Seror R" first="Raphaèle" last="Seror">Raphaèle Seror</name><affiliation wicri:level="4"><nlm:affiliation>INSERM U1184, Assistance Publique-Hôpitaux de Paris (AP-HP), Center of Research on Immunology of Viral and Autoimmune Diseases (IMVA), Université Paris-Sud, Le Kremlin Bicêtre, France; Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Hôpital Bicêtre, 78 rue du Général Leclerc, Le Kremlin Bicêtre 94275, France. Electronic address: raphaele.se@gmail.com.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1184, Assistance Publique-Hôpitaux de Paris (AP-HP), Center of Research on Immunology of Viral and Autoimmune Diseases (IMVA), Université Paris-Sud, Le Kremlin Bicêtre, France; Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Hôpital Bicêtre, 78 rue du Général Leclerc, Le Kremlin Bicêtre 94275</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="university">Université Paris-Sud</orgName></affiliation></author><author><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name><affiliation wicri:level="4"><nlm:affiliation>INSERM U1184, Assistance Publique-Hôpitaux de Paris (AP-HP), Center of Research on Immunology of Viral and Autoimmune Diseases (IMVA), Université Paris-Sud, Le Kremlin Bicêtre, France; Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Hôpital Bicêtre, 78 rue du Général Leclerc, Le Kremlin Bicêtre 94275, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1184, Assistance Publique-Hôpitaux de Paris (AP-HP), Center of Research on Immunology of Viral and Autoimmune Diseases (IMVA), Université Paris-Sud, Le Kremlin Bicêtre, France; Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Hôpital Bicêtre, 78 rue du Général Leclerc, Le Kremlin Bicêtre 94275</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="university">Université Paris-Sud</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27890173</idno><idno type="pmid">27890173</idno><idno type="doi">10.1016/j.rdc.2016.09.006</idno><idno type="wicri:Area/PubMed/Corpus">000C91</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C91</idno><idno type="wicri:Area/PubMed/Curation">000C91</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C91</idno><idno type="wicri:Area/PubMed/Checkpoint">000B14</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B14</idno><idno type="wicri:Area/Ncbi/Merge">001400</idno><idno type="wicri:Area/Ncbi/Curation">001400</idno><idno type="wicri:Area/Ncbi/Checkpoint">001400</idno><idno type="wicri:Area/Main/Merge">001753</idno><idno type="wicri:Area/Main/Curation">001754</idno><idno type="wicri:Area/Main/Exploration">001754</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Malignancy and the Risks of Biologic Therapies: Current Status.</title><author><name sortKey="Seror, Raphaele" sort="Seror, Raphaele" uniqKey="Seror R" first="Raphaèle" last="Seror">Raphaèle Seror</name><affiliation wicri:level="4"><nlm:affiliation>INSERM U1184, Assistance Publique-Hôpitaux de Paris (AP-HP), Center of Research on Immunology of Viral and Autoimmune Diseases (IMVA), Université Paris-Sud, Le Kremlin Bicêtre, France; Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Hôpital Bicêtre, 78 rue du Général Leclerc, Le Kremlin Bicêtre 94275, France. Electronic address: raphaele.se@gmail.com.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1184, Assistance Publique-Hôpitaux de Paris (AP-HP), Center of Research on Immunology of Viral and Autoimmune Diseases (IMVA), Université Paris-Sud, Le Kremlin Bicêtre, France; Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Hôpital Bicêtre, 78 rue du Général Leclerc, Le Kremlin Bicêtre 94275</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="university">Université Paris-Sud</orgName></affiliation></author><author><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name><affiliation wicri:level="4"><nlm:affiliation>INSERM U1184, Assistance Publique-Hôpitaux de Paris (AP-HP), Center of Research on Immunology of Viral and Autoimmune Diseases (IMVA), Université Paris-Sud, Le Kremlin Bicêtre, France; Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Hôpital Bicêtre, 78 rue du Général Leclerc, Le Kremlin Bicêtre 94275, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U1184, Assistance Publique-Hôpitaux de Paris (AP-HP), Center of Research on Immunology of Viral and Autoimmune Diseases (IMVA), Université Paris-Sud, Le Kremlin Bicêtre, France; Department of Rheumatology, Hôpitaux Universitaires Paris-Sud, Hôpital Bicêtre, 78 rue du Général Leclerc, Le Kremlin Bicêtre 94275</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="university">Université Paris-Sud</orgName></affiliation></author></analytic><series><title level="j">Rheumatic diseases clinics of North America</title><idno type="eISSN">1558-3163</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antirheumatic Agents (adverse effects)</term><term>Biological Products (adverse effects)</term><term>Humans</term><term>Neoplasms (chemically induced)</term><term>Neoplasms (immunology)</term><term>Rheumatic Diseases (drug therapy)</term><term>Rheumatic Diseases (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antirhumatismaux (effets indésirables)</term><term>Humains</term><term>Produits biologiques (effets indésirables)</term><term>Rhumatismes (immunologie)</term><term>Rhumatismes (traitement médicamenteux)</term><term>Tumeurs ()</term><term>Tumeurs (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antirheumatic Agents</term><term>Biological Products</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antirhumatismaux</term><term>Produits biologiques</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Rhumatismes</term><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Neoplasms</term><term>Rheumatic Diseases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Rhumatismes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Tumeurs</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cancer is a common event in patients with rheumatic diseases. In some cases, the disease, its risk factors, or its treatment could play a role in favoring cancer. This article analyzes the current knowledge on the risk of malignancy associated with biologics in rheumatic diseases and discusses some methodological issues to be considered when evaluating the association between disease, treatments, and the risk of cancer. This article focuses on the risk of overall malignancy but also of skin cancer, lymphoma, and recurrent cancer associated with all biologics marketed for the treatment of rheumatic diseases.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><orgName><li>Université Paris-Sud</li></orgName></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Seror, Raphaele" sort="Seror, Raphaele" uniqKey="Seror R" first="Raphaèle" last="Seror">Raphaèle Seror</name></region><name sortKey="Mariette, Xavier" sort="Mariette, Xavier" uniqKey="Mariette X" first="Xavier" last="Mariette">Xavier Mariette</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001754 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001754 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27890173
|texte= Malignancy and the Risks of Biologic Therapies: Current Status.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27890173" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |